您的位置：山东大学 -> 科技期刊社 -> 《山东大学学报（医学版）》

山东大学学报（医学版） ›› 2014, Vol. 52 ›› Issue (8): 22-26.doi: 10.6040/j.issn.1671-7554.0.2014.041

• 基础医学 • 上一篇    下一篇

甲状旁腺激素对骨质疏松种植体骨结合的影响

狄婧1, 石晓婷2, 李雪3, 林志勇1, 孙哲1, 邓凤英1   

  1. 1. 山东大学附属省立医院口腔内科, 山东 济南 250021;
    2. 天津市口腔医院儿童口腔科, 天津 300041;
    3. 山东医学高等专科学校口腔医学系, 山东 济南 250014
  • 收稿日期:2014-01-15 修回日期:2014-06-10 出版日期:2014-08-10 发布日期:2014-08-10
  • 通讯作者: 林志勇。E-mail：zhiyongl@126.com E-mail:zhiyongl@126.com
  • 基金资助:
    山东省科技发展基金资助项目（2010G0020226）

Effect of parathyroid hormone1-34 on bone healing around dental implants in ostoeporotic rats

DI Jing1, SHI Xiaoting2, LI Xue3, LIN Zhiyong1, SUN Zhe1, DENG Fengying1   

  1. 1. Department of Oral Medicine, Shandong Provincial Hospital Affiliated to Shandong University, Jinan 250021, Shandong, China;
    2. Department of Pediatric Dentistry, Tianjin Stomatological Hospital, Tianjin 300041, China;
    3. Department of Stomatology, Shandong Medical College, Jinan 250014, Shandong, China
  • Received:2014-01-15 Revised:2014-06-10 Online:2014-08-10 Published:2014-08-10

PDF (PC)

104

摘要： 目的 研究甲状旁腺激素（PTH1-34）对骨质疏松种植体骨结合的影响。方法 36只雌性Wistar大鼠随机分为假手术组、去势组和去势加PTH1-34治疗组，每组12只。假手术组接受假手术，去势组和去势加PTH1-34治疗组行双侧卵巢切除术。术后8周测量胫骨骨密度，证实骨质疏松状态。同时在3组大鼠右侧胫骨近干骺端分别植入纯钛螺纹柱状种植体，假手术组和去势组用生理盐水1 mL/kg，去势加PTH1-34治疗组用PTH1-3420 μg/kg，隔日腹腔注射1次，用药8周。种植术用药4、8周后处死各组半数大鼠，标本制作带种植体的骨组织磨片，行组织学观察及骨计量学测量。结果 种植术后第4周，去势加PTH1-34治疗组骨小梁平均宽度、种植体骨结合率和结合骨板宽度均显著高于去势组（P<0.05），而去势加PTH1-34治疗组种植体骨结合率与假手术组相比，差异无统计学意义（P>0.05）。种植术后第8周，去势加PTH1-34治疗组松质骨区骨量、骨小梁平均宽度、种植体骨结合率和结合骨板宽度较去势组均有明显提高（P<0.05），与假手术组相比，差异无统计学意义（P>0.05）。结论 骨质疏松对种植界面早期骨结合有一定的影响，间歇性、小剂量注射PTH1-34可有效促进骨形成，从而提高种植体骨结合的质量。

关键词: 骨质疏松, 骨结合, 种植体, 甲状旁腺激素

Abstract: Objective To investigate the effect of parathyroid hormone1-34 (PTH1-34) on bone healing around dental implants in ostoeporotic rats. Methods A total of 36 female Wistar rats were randomly divided into the sham-operation group, ovariectomized group and ovariectomized with PTH1-34 treatment group, with 12 in each group. Animals in the sham-operation group underwent sham-operation, while rats in ovariectomized group and ovariectomized with PTH1-34 treatment group received bilateral ovariectomy. Eight weeks after surgery, tibia of rats was examined for bone mineral density to verify osteoporosis status. At the same time, Pure screw titanium implant was placed in the right tibia near metaphysis. Every other day for 8 weeks, normal saline 1 mL/kg was intraperitoneally injected in rats in sham-operation group and ovariectomized group, while PTH1-34 20 μg/kg in rats in the ovariectomized with PTH1-34 treatment group. In week 4 and 8 after implantation surgery, half of the rats in each group were killed. Undecalcified sections were preparedand examined histologically and histomorphometrically. Results In week 4, the trabercular width (TW), implant bone contact rate (IBCR), combinded bone lamella width (CBLW) of rats in ovariectomized with PTH1-34 treatment group were much higher than those of rats in ovariectomized group (P<0.05). In terms of IBCR, there was no difference between ovariectomized with PTH1-34 treatment group and sham-operation group (P>0.05). In week 8, trabercular area (TA), TW, IBCR and CBLW were significantly elevated in ovariectomized with PTH1-34 treatment group when compared with ovariectomized group (P<0.05). There was no difference between ovariectomized with PTH1-34 treatment group and sham-operation group in all parameters (P>0.05). Conclusion Osteoporosis impedes osseointegration in ovariectomized rats. Intermittent application of parathyroid hormone1-34 with small doses can promote bone formation effectively to improve the osseointegration quality of rats.

Key words: Osteoporosis, Parathyroid hormone, Dental implants, Osseointegration

中图分类号: 

  • R782.1
[1] Keller J C, Stewart M, Roehm M, et al. Osteoporosis-like bone conditions affect osseointegration of implants[J]. Int J Oral Maxillofac Implants, 2004, 19(5):687-694.
[2] Hwang D, Wang H L. Medical contraindications to implant therapy PartII: Relative contraindications[J]. Implant Dent, 2007, 16(1):13-23.
[3] Beppu K, Kido H, Watazu A, et al. Peri-implant bone density in senile osteoporosis-changes from implant placement to osseointegration[J]. Clin Implant Dent Relat Res, 2013, 15 (2):217-226.
[4] Qi M C, Zhou X Q, Hu J, et al. Oestrogen replacement therapy promotes bone healing around dental implants in osteoporotic rats[J]. Int J Oral Maxillofac Surg, 2004, 33(3):279-285.
[5] 朱显军, 张学军, 李蓬秋, 等. 重组人甲状旁腺素(1-34)对绝经后骨质疏松症的治疗作用研究[J]. 四川医学, 2011, 32(7):1020-1023.
[6] Pettway G J, Meganck J A, Koh A J, et al. Parathyroid hormone mediates bone growth through the regulation of osteoblast proliferation and differentiation[J]. Bone, 2008, 42(4):806-818.
[7] Syed F, Khosla S. Mechanisms of sex steroid effects on bone[J]. Biochem Biophys Res Commun, 2005, 328(3):688-696.
[8] Amorim M A, Takayama L, Jorgetti V, et al. Comparative study of axial and femoral bone mineral density and parameters of mandibular bone quality in patients receiving dental implants[J]. Chteoporos, 2007, 18(5):703-709.
[9] Dvorak G, Arnhart C, Heuberer S, et al. Peri-implantitis and late implant failures in postmenopausal women: a cross-sectional study[J]. J Clin Periodontol, 2011, 38(10):950-955.
[10] Zhang X Z, Wang B, Yang J, et al. A randomized, multicenter controlled trial to compare the efficacy of recombinant human parathyroid hormone (1-34) with elcatonin in postmenopausal women with osteoporosis in China[J]. Chin Med J, 2009, 122(24):103-115.
[11] Alkhiary Y M, Gerstenfeld L C, Krall E, et al. Enhancement of ex-perimental fracture-healing by systemic administration of recombinant human parathyroid hormone (1-34)[J]. Bone Joint Surg Am, 2005, 87(4):731-741.
[12] Guo Y S, Yuan W J, Zhang A P, et al. Parathyroid hormone-mitogen-activated protein kinase axis exerts fibrogenic effect of connective tissue growth factor on human renal proximal tubular cells[J]. Chin Med J, 2010,123(24):273-277.
[13] 于志峰, 金慰芳, 顾淑珠, 等. rhPTH(1-34)治疗OVX大鼠骨质疏松延后效应的初步研究[J]. 中国骨质疏松杂志, 2005, 11(2):278-280.
[14] Cosman F, Lane N E, Bolognese M A, et al. Effect of transdermal teriparatide administration on bone mineral density in postmenopausal women[J]. JCEM, 2010, 95(1):151-158.
[15] Gabet Y, Muller R, Levy J, et al. Parathyroid hormone1-34 enhances titanium implant anchorage in low-density trabecular bone: a correlative micro-computed tomographic and biomechanical analysis[J]. Bone, 2006, 39(2):276-282.
[16] Skripitz R, Johansson H R, Ulrich S D, et al. Effect of alendronate and intermittent parathyroid hormone on implant fixation in ovariectomized rats[J]. J Orthop Sci, 2009, 14(2):138-143.
[17] 李裕明, 邓波. 甲状旁腺激素在骨质疏松症治疗中的作用[J]. 临床内科杂志, 2009, 26(3):152-154.
[1] 徐大霞,侯楠,李晓峰,王闯,孔猛,焦广俊,陈允震. 糖皮质激素性骨质疏松症骨代谢与糖皮质激素用药时间的相关性[J]. 山东大学学报（医学版）, 2017, 55(5): 103-107.
[2] 常飞,姜宝岐,董作青,刘佳,徐欣. 关于初期稳定性对即刻种植成功率影响的动物实验研究[J]. 山东大学学报（医学版）, 2017, 55(3): 54-58.
[3] 冯潇雨, 张洪美, 车选强, 康东红. 成骨细胞刺激因子对去卵巢骨质疏松大鼠的治疗效果[J]. 山东大学学报（医学版）, 2015, 53(7): 8-12.
[4] 杜腾飞, 刘国明, 郭小美, Ching-Chang Ko, 商红国. 甲状旁腺激素对大鼠牵张成骨过程中ONC、OPN、C-FOS、COL1、VEGF、RUNX2、ALP基因表达的影响[J]. 山东大学学报（医学版）, 2015, 53(3): 32-35.
[5] 闫长红, 于铭. 经皮球囊扩张椎体后凸成形术治疗 老年骨质疏松性椎体压缩性骨折的护理体会[J]. 山东大学学报（医学版）, 2014, 52(Z2): 167-168.
[6] 蔡宇, 张颖, 徐成. 维持性血液透析患者肾性骨病预防和护理[J]. 山东大学学报（医学版）, 2014, 52(Z1): 154-155.
[7] 张丽, 严红. 2型糖尿病患者骨质疏松情况调查[J]. 山东大学学报（医学版）, 2014, 52(S2): 107-107.
[8] 刘金伟1，刘海春1，武文亮1， 陈良2，李尚志1，曹聪1，陈允震1. 可调式外固定支架构建大鼠股骨骨质疏松骨不连模型[J]. 山东大学学报（医学版）, 2014, 52(6): 33-36.
[9] 樊庆凯, 龚维明, 宁斌, 宋宏亮, 蔚建鲁, 贾堂宏. PKP治疗骨质疏松性多节段椎体压缩性骨折的临床疗效[J]. 山东大学学报（医学版）, 2014, 52(11): 73-76.
[10] 胡苏1,2，逄曙光2，崔莹2，于春晓1，赵家军1，管庆波1. 链脲佐菌素诱导糖尿病大鼠骨髓间充质干细胞成骨分化[J]. 山东大学学报(医学版), 2013, 51(8): 7-12.
[11] 张洪美1，王燕2，康东红1，曹维1，刘涛1，王萍1. 济南市城区健康成年男性腰椎和股骨的骨密度分析[J]. 山东大学学报(医学版), 2013, 51(4): 67-70.
[12] 艾尔肯·肉孜，王鑫. 经皮椎体成形术治疗老年人椎体骨质疏松压缩性骨折[J]. 山东大学学报(医学版), 2011, 49(5): 163-164.
[13] 丁岩，陈允震，刘海春，陈剑，赵华，王洪亮，焦广俊. 指数曲线电刺激治疗原发性骨质疏松[J]. 山东大学学报(医学版), 2010, 48(3): 70-73.
[14] 刘海春 张剑锋 陈允震. 骨质疏松大鼠股骨生物力学特性与骨胶原质量变化的相关研究[J]. 山东大学学报(医学版), 2009, 47(5): 42-45.
[15] 信维伟，程光齐，朱颖华，李展春. 经皮椎体成形术治疗骨质疏松性骨折的应用体会[J]. 山东大学学报(医学版), 2009, 47(11): 135-137.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
版权所有 © 2018 《山东大学学报(医学版)》编辑部　
地址:山东大学科技期刊社（济南市历城区山大南路27号山东大学中心校区明德楼B座721室） 电话: 0531-88366918 E-mail: xbyxb@sdu.edu.cn
本系统由北京玛格泰克科技发展有限公司设计开发